{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:15:48Z","timestamp":1792034148097,"version":"4.4.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.annonc.2021.02.015","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T20:34:31Z","timestamp":1614976471000},"page":"710-725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":145,"title":["The systemic treatment of recurrent ovarian cancer revisited"],"prefix":"10.1016","volume":"32","author":[{"given":"T.","family":"Baert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Blecharz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.P.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Querleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"May","key":"10.1016\/j.annonc.2021.02.015_bib1","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.02.015_bib2","article-title":"Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III\/ENGOT-ov20","volume":"38","author":"du Bois","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.02.015_bib3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials","volume":"59","author":"Blackledge","year":"1989","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib4","first-page":"207","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.02.015_bib5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.02.015_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1992.10.4.513","article-title":"Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population","volume":"10","author":"Markman","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2021.02.015_bib7","first-page":"87","article-title":"Advanced epithelial ovarian cancer: 1998 consensus statements","volume":"10","author":"Berek","year":"1998","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.02.015_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","article-title":"Second-line treatment of ovarian cancer","volume":"5","author":"Markman","year":"2000","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.annonc.2021.02.015_bib9","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2021.02.015_bib10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdx010","article-title":"Fifth Ovarian Cancer Consensus Conference\u202f: individualized therapy and patient factors","volume":"28","author":"Mcgee","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2018.05.020","article-title":"Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance","volume":"150","author":"Lindemann","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"21","key":"10.1016\/j.annonc.2021.02.015_bib12","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group","volume":"30","author":"Alsop","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ygyno.2015.05.042","article-title":"Phase II study of weekly paclitaxel\/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers\u202f: a study in 108 patients by the Belgian Gynaecological Oncology Group","volume":"138","author":"Vergote","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2021.02.015_bib14","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1158\/1078-0432.CCR-10-0832","article-title":"Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer","volume":"16","author":"Ledermann","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2021.02.015_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjc.6600002","article-title":"Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer","volume":"86","author":"van der Burg","year":"2002","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.02.015_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/gyno.2002.6855","article-title":"Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients","volume":"88","author":"Nagourney","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.02.015_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.2002.6850","article-title":"Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ygyno.2006.03.018","article-title":"Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group","volume":"103","author":"Brewer","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.02.015_bib19","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ygyno.2006.09.006","article-title":"Biweekly gemcitabine and cisplatin in platinum-resistant\/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma","volume":"104","author":"Bozas","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.02.015_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/gyno.2002.6859","article-title":"Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer","volume":"88","author":"Havrilesky","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.02.015_bib21","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.ejca.2012.11.027","article-title":"Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer","volume":"49","author":"van der Burg","year":"2013","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","article-title":"Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)","volume":"23","author":"Lortholary","year":"2012","journal-title":"Ann Oncol"},{"issue":"9375","key":"10.1016\/j.annonc.2021.02.015_bib23","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.annonc.2021.02.015_bib24","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"10.1016\/j.annonc.2021.02.015_bib25","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/annonc\/mdl376","article-title":"Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial","volume":"18","author":"Ferrero","year":"2007","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.02.015_bib27","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1023\/A:1011605008922","article-title":"Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer\u2014a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group","volume":"12","author":"du Bois","year":"2001","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.02.015_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6\u201312 months) subpopulation of OVA-301 phase III randomized trial","volume":"22","author":"Poveda","year":"2011","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2021.02.015_bib29","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.02.015_bib30","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.02.015_bib31","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2021.02.015_bib32","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.02.015_bib33","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study","volume":"14","author":"Creemers","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.02.015_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/annonc\/mdh025","article-title":"Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma","volume":"15","author":"ten Bokkel Huinink","year":"2004","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1016\/j.annonc.2021.02.015_bib35","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","article-title":"Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study","volume":"35","author":"Pignata","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2021.02.015_bib36","article-title":"INOVATYON study: randomized phase III international study comparing trabectedin\/PLD followed by platinum at progression vs carboplatin\/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line","volume":"31","author":"Colombo","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2021.02.015_bib37","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/IGC.0b013e3181a418ff","article-title":"Carboplatin hypersensitivity does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study","volume":"19","author":"Gomez","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2021.02.015_bib38","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/annonc\/mds538","article-title":"A\u00a0prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer","volume":"24","author":"Lee","year":"2013","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.02.015_bib39","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","article-title":"Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy","volume":"88","author":"Kamura","year":"2000","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.02.015_bib40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11912-020-0872-5","article-title":"Low-grade serous tumors: are we making progress?","volume":"22","author":"Pauly","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"10.1016\/j.annonc.2021.02.015_bib41","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.09.023","article-title":"Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel\/carboplatin chemotherapy: cell type is the most useful prognostic factor","volume":"48","author":"Bamias","year":"2011","journal-title":"Eur J Cancer"},{"issue":"22","key":"10.1016\/j.annonc.2021.02.015_bib42","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1158\/0008-5472.CAN-12-0324","article-title":"Clinicopathological features of homologous recombination\u2014deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival","volume":"72","author":"Mukhopadhyay","year":"2012","journal-title":"Cancer Res"},{"issue":"34","key":"10.1016\/j.annonc.2021.02.015_bib43","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.02.015_bib44","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7553","key":"10.1016\/j.annonc.2021.02.015_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2020.01.038","article-title":"CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes","volume":"157","author":"Petersen","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.02.015_bib47","doi-asserted-by":"crossref","first-page":"e11198","DOI":"10.1371\/journal.pone.0011198","article-title":"Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma","volume":"5","author":"Jinawath","year":"2010","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.annonc.2021.02.015_bib48","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/annonc\/mdt406","article-title":"Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data","volume":"24","author":"Raja","year":"2013","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2021.02.015_bib49","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","article-title":"Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"26","author":"Sehouli","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"29","author":"Sehouli","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 8","key":"10.1016\/j.annonc.2021.02.015_bib51","first-page":"932O","article-title":"Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: results of CORAIL trial","volume":"29","author":"Gaillard","year":"2018","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.annonc.2021.02.015_bib52","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.02.015_bib53","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"6801","key":"10.1016\/j.annonc.2021.02.015_bib54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.annonc.2021.02.015_bib55","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.annonc.2021.02.015_bib56","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.02.015_bib57","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel\u2013carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.02.015_bib58","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S1470-2045(18)30372-3","article-title":"Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Chekerov","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.02.015_bib59","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2017.4218","article-title":"Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial","volume":"4","author":"Richardson","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10023","key":"10.1016\/j.annonc.2021.02.015_bib61","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.annonc.2021.02.015_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2016.07.112","article-title":"Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2","volume":"143","author":"Monk","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.02.015_bib63","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2010.34.3178","article-title":"Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer","volume":"30","author":"Karlan","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"10.1016\/j.annonc.2021.02.015_bib64","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","article-title":"Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer","volume":"29","author":"Ledermann","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.02.015_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2014.03.157","article-title":"Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer","volume":"133","author":"Aghajanian","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2021.02.015_bib66","first-page":"9","article-title":"Comment: Platinum-sensitive ovarian cancer: liminal advances","volume":"2045","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.annonc.2021.02.015_bib67","article-title":"Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17","volume":"36","author":"Pignata","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"7035","key":"10.1016\/j.annonc.2021.02.015_bib68","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"7035","key":"10.1016\/j.annonc.2021.02.015_bib69","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib70","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"25","key":"10.1016\/j.annonc.2021.02.015_bib71","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.18.02050","article-title":"Moving from poly (ADP-Ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy","volume":"37","author":"Gourley","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2021.02.015_bib72","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2021.02.015_bib73","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10106","key":"10.1016\/j.annonc.2021.02.015_bib74","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.annonc.2021.02.015_bib75","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2021.02.015_bib76","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.02.015_bib77","article-title":"Final overall survival (OS) results from SOLO2\/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation","volume":"38","author":"Poveda","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00008","article-title":"Reversal of bowel obstruction with platinum-based chemotherapy and olaparib in recurrent, short platinum-free interval, RAD51C germline mutation\u2013associated ovarian cancer","author":"Ngoi","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2021.02.015_bib79","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1158\/1078-0432.CCR-17-1337","article-title":"FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer","volume":"23","author":"Balasubramaniam","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.annonc.2021.02.015_bib80","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib81","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ygyno.2020.02.030","article-title":"Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma","volume":"157","author":"Wolford","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.02.015_bib82","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial","volume":"38","author":"Penson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl no. 15","key":"10.1016\/j.annonc.2021.02.015_bib83","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1200\/JCO.2019.37.15_suppl.5507","article-title":"Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer","volume":"37","author":"Vanderstichele","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.02.015_bib84","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.02.015_bib85","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol"},{"issue":"suppl 3","key":"10.1016\/j.annonc.2021.02.015_bib86","doi-asserted-by":"crossref","first-page":"S545","DOI":"10.1016\/S0959-8049(16)31512-X","article-title":"A\u00a0phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation","volume":"51","author":"Shapira-frommer","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.02.015_bib87","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.02.015_bib88","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","article-title":"A\u00a0phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation\u2014an NRG","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecol. Oncol"},{"key":"10.1016\/j.annonc.2021.02.015_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2020.06.033","article-title":"Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer","author":"Loverix","year":"2020","journal-title":"Soc Gynecol Oncol"},{"issue":"26","key":"10.1016\/j.annonc.2021.02.015_bib90","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.annonc.2021.02.015_bib91","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.annonc.2021.02.015_bib92","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Coquard","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2021.02.015_bib93","article-title":"OREO\/ENGOT OV-38: a phase IIIB trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer","volume":"28","author":"Pujade-lauraine","year":"2017","journal-title":"Ann Oncol"},{"issue":"492","key":"10.1016\/j.annonc.2021.02.015_bib94","doi-asserted-by":"crossref","first-page":"eaav4508","DOI":"10.1126\/scitranslmed.aav4508","article-title":"Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51","volume":"11","author":"Kaplan","year":"2019","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.annonc.2021.02.015_bib95","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.02.015_bib96","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/annonc\/mdz018","article-title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.02.015_bib97","article-title":"A\u00a0phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer","volume":"38","author":"Liu","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib98","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2019.08.024","article-title":"Overall survival results of AGO-OVAR16: a phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer","volume":"155","author":"Vergote","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"suppl 8","key":"10.1016\/j.annonc.2021.02.015_bib99","article-title":"BAROCCO: a randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer","volume":"29","author":"Colombo","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2021.02.015_bib100","article-title":"OCTOVA: a randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinum-resistant ovarian cancer","volume":"28","author":"Nicum","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.02.015_bib101","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ygyno.2016.05.007","article-title":"Ovarian cancer and the immune system\u2014the role of targeted therapies","volume":"142","author":"Turner","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2021.02.015_bib102","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.gore.2017.01.002","article-title":"Ovarian cancer and the immune system","volume":"19","author":"Baert","year":"2017","journal-title":"Gynecol Oncol Rep"},{"issue":"3","key":"10.1016\/j.annonc.2021.02.015_bib103","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN Solid Tumor Trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2021.02.015_bib104","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.02.015_bib105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2019.02.014","article-title":"Combining conventional therapy with immunotherapy: a risky business?","volume":"113","author":"Coosemans","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.02.015_bib106","first-page":"LBA25","article-title":"Avelumab in combination with and\/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: results from the phase 3 JAVELIN ovarian 100 trial","author":"Ledermann","year":"2020","journal-title":"Soc Gynecol Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2021.02.015_bib107","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.02.015_bib108","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.annonc.2021.02.015_bib109","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/bjc.2017.376","article-title":"Combining DNA damaging therapeutics with immunotherapy: more haste, less speed","volume":"118","author":"Brown","year":"2018","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2021.02.015_bib110","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.annonc.2021.02.015_bib111","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2021.02.015_bib112","article-title":"Phase II study of olaparib\u00a0+ durvalumab (MEDIOLA): updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)","volume":"30","author":"Drew","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.02.015_bib113","article-title":"ENGOT-Ov41\/GEICO-69-O\/ANITA trial: a phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or perit","volume":"37","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.02.015_bib114","doi-asserted-by":"crossref","first-page":"a027094","DOI":"10.1101\/cshperspect.a027094","article-title":"Reengineering the tumor microenvironment heterogeneity to alleviate hypoxia and overcome cancer heterogneity","volume":"6","author":"Martin","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"10.1016\/j.annonc.2021.02.015_bib115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PPO.0000000000000327","article-title":"Combinations of bevacizumab with cancer immunotherapy","volume":"24","author":"Chen","year":"2018","journal-title":"Cancer J"},{"issue":"19","key":"10.1016\/j.annonc.2021.02.015_bib116","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","article-title":"Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women's cancers: a dose-esc","volume":"35","author":"Lee","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.02.015_bib117","article-title":"AGO-OVAR 2.29 (ENGOT-ov34): atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC)","volume":"37","author":"Marm\u00e9","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.02.015_bib118","article-title":"ATALANTE (ENGOT-ov29): a randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab","volume":"36","author":"Kurtz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.02.015_bib119","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"issue":"13","key":"10.1016\/j.annonc.2021.02.015_bib120","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockler","year":"2014","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421001551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421001551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:02:51Z","timestamp":1760335371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421001551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":120,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0923753421001551"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.02.015","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The systemic treatment of recurrent ovarian cancer revisited","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}